Dagla

Dagla

Itopride

Symptomatic treatment of functional non-ulcer dyspepsia (chronic gastritis), in particular — relief of bloating (flatulence), pain or discomfort in the epigastric region (gastralgia), anorexia, heartburn, nausea, vomiting, feelings of rapid satiety.

Inside, before meals, 50 mg 3 times a day.

The recommended daily dose is 150 mg.

The indicated dose can be reduced taking into account the age of the patient.

hypersensitivity to itoprid or any auxiliary component of the drug,

gastrointestinal bleeding,

mechanical obstruction and perforation of the gastrointestinal tract,

lactase deficiency, lactose intolerance, glucose-galactose malabsorption, because the dosage form contains lactose,

pregnancy,

lactation period (breastfeeding),

children under 16 years of age.

With caution: you should use the drug Dagla^® in patients for whom the appearance of cholinergic adverse reactions (associated with an increase in the action of acetylcholine under the influence of the drug), may worsen the course of existing diseases.

From the side of the hematopoietic organs: leukopenia, thrombocytopenia.

Allergic reactions: flushing of the skin, pruritus, rash, urticaria, anaphylactic shock.

From the endocrine system: gynecomastia, hyperprolactinemia.

From the digestive system: increased salivation, nausea, diarrhea, constipation, abdominal pain, jaundice.

From the nervous system: headache, dizziness, tremor, sleep disturbance, irritability.

Laboratory parameters: increased activity of AST, ALT, γ-glutamyl transferase, alkaline phosphatase, hyperbilirubinemia.

Cases of overdose in humans are not described.

Treatment: in case of possible overdose, gastric lavage and symptomatic therapy are indicated.

Itopride hydrochloride increases the motility of the gastrointestinal tract due to antagonism with D₂- dopamine receptors and inhibition of acetylcholinesterase. Itopride hydrochloride activates the release of acetylcholine, suppresses its destruction. It has an antiemetic effect due to the blockade of D₂- receptors located in the trigger zone. Causes dose-dependent suppression of vomiting caused by apomorphine.

Itopride hydrochloride activates the propulsive motility of the stomach due to antagonism with D₂- receptors and dose-dependent inhibition of acetylcholinesterase activity.

Itopride hydrochloride has a specific effect on the upper gastrointestinal tract, accelerates transit through the stomach, improves its emptying.

It does not affect the serum concentrations of gastrin.

Suction. Itopride hydrochloride is rapidly and well absorbed in the gastrointestinal tract. The relative bioavailability of 60%. C_max in the blood plasma of 0.28 µg/ml. T_max in blood plasma-0.5-0.75 hours after taking 50 mg of the drug. With repeated administration of 50-200 mg 3 times a day for 7 days, the pharmacokinetics is linear, the accumulation of the drug is minimal.

The binding to plasma proteins (mainly albumin) is 96%, with α₁- acidic glycoprotein-less than 15%.

Distribution. Itopride hydrochloride is distributed in the kidneys, small intestine, liver, adrenal glands, and stomach. V_d — 6.1 l/kg.

In therapeutic doses, it slightly penetrates into the brain and spinal cord, as well as breast milk.

Metabolism and excretion. The drug is metabolized in the liver by the action of flavin-dependent monooxygenase.

3 metabolites were identified, only one of them shows insignificant activity (2-3% of the activity of itopride hydrochloride), which has no pharmacological significance.

Itopride hydrochloride and its metabolites are mainly excreted by the kidneys. T_1/2 - is 6 hours, in patients with trimethylaminuria T_1/2 increases.

• The motility of the gastrointestinal tract stimulant — acetylcholine release stimulant [Other gastrointestinal agents]

Accelerates the absorption of other drugs (cimetidine, ranitidine, teprenone, cetraxate).

The prokinetic effect of the drug does not change under the influence of drugs that reduce the acidity of gastric juice.

M-holinoblokatory lower efficiency itopride.

The cholinergic effect of itopride may increase with simultaneous administration of m-cholinoblockers, as well as cholinesterase inhibitors.